CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Immunofree tablets and Reginmune capsuleWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D014777 Virus Diseases NIH 0.12

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 An Open Label, Multicenter, Randomized, Controlled, Clinical Study to Evaluate the Efficacy and Safety of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets Compared With Standard Treatment Protocol in the Treatment of Mild to Moderate COVID-19 Patients.

While novel drug discovery and vaccine studies are time taking process, re-purposing old drugs against the COVID-2019 epidemic can help identify treatments, with known pre-clinical, pharmacokinetic, pharmacodynamic, and toxicity profiles, which can rapidly enter Phase 3 or 4 or can be used directly in clinical settings. Immunofree has many of the herbs which have been evaluated by other trials published for Covid-19 treatment. The Immunofree tablet of the test product is an Ayurvedic proprietary medicine and is a combination of polyherbal mixture. The components of this formulation are known for their anti-viral and immunomodulatory effects. Also, Reginmune, owing to its immunomodulatory effect might help in easing the symptoms and decrease the viral load.

NCT04494204 Treatment of Covid-19 Virus Infection Combination Product: Immunofree tablets and Reginmune capsule
MeSH:Virus Diseases

Primary Outcomes

Description: This includes overall time it takes for negative covid-19 results, improvement based on a customized questionnaire for fever, cough, body ache, loss of taste or smell, or other similar conditions

Measure: Time (Days) to clinical improvement from study enrollment

Time: Day 0 - Day 10

Secondary Outcomes

Description: Being an important part, each patient has to be monitored for oxygen saturation level, and this would help us analyze when a subject enters from Mild to moderate stage

Measure: Proportion of participants in each group with oxygen saturation more than 94% on room air for more than 24h

Time: Day 0, Day 5±1 and Day of discharge i.e Day 10±1

Description: D Dimer levels has to be measured to study the D dimer levels of the patient as most researchers claiming covid-19 to be relative to coagulation. This study will help us identity the same.

Measure: Value of coagulation indicators

Time: Day 0, Day 5±1 and Day of discharge i.e Day 10±1

Description: via ICMR recognized RT-PCR to identify when a patient is coronavirusfree

Measure: Time to first negative SARS-CoV-2 PCR in NP swab

Time: Day 0, Day 5±1 and Day of discharge i.e Day 10±1

Description: To identify how long a patient needs oxygen therapy in certain case

Measure: Duration of oxygen therapy

Time: upto day 10+1

Description: This is considered as a part of pharmacovigilance, as how many people enters moderate to severe case, if any

Measure: Proportion of participants in each group with need for mechanical ventilation

Time: upto day 10+1

Description: most mild cases that becomes asymptomatic are sent back from hospital and treated at home quarantine. this is to identify when a patient becomes asymptomatic

Measure: Duration of hospitalization

Time: upto day 10+1

No related HPO nodes (Using clinical trials)